Hot Pursuit     12-May-20
Ind-Swift Labs hits the roof after Punjab facility gets EIR
Ind-Swift Laboratories hit an upper circuit of 5% at Rs 21.65 after the company said its manufacturing facility at Derabassi in Punjab received establishment inspection report (EIR) from the US drug regulator.
The United States Food and Drug Administration (USFDA)'s inspection was conducted from 9 to 13 March 2020. The EIR has been issued without any FORM 483 observations.

This is the sixth successful USFDA inspection completed by the company. Ind- Swift Supplies 15 APIs (Active Pharmaceutical Ingredients) to its customers based in the US. The APIs manufactured from the Derabassi facility are supplied to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe, the company said in a statement.

Ind-Swift Laboratories manufactures bulk drugs and intermediates. The company's product portfolio includes anti-infective, anti-allergy, analgesic and cardiovascular medicines.

Previous News
  Ind-Swift Laboratories consolidated net profit rises 38.79% in the December 2021 quarter
 ( Results - Announcements 08-Feb-22   18:07 )
  Ind-Swift Laboratories schedules board meeting
 ( Corporate News - 25-Jun-24   10:22 )
  Indices nudge higher; Nifty above 23,550
 ( Market Commentary - Mid-Session 25-Jun-24   09:32 )
  Ind-Swift Labs set to launch anti-allergic drug in US; shares hit the roof
 ( Hot Pursuit - 16-Jun-20   15:08 )
  Ind-Swift Laboratories reports consolidated net loss of Rs 61.45 crore in the March 2022 quarter
 ( Results - Announcements 29-May-22   08:40 )
  Ind-Swift Laboratories consolidated net profit rises 71.55% in the December 2022 quarter
 ( Results - Announcements 15-Feb-23   07:45 )
  Ind-Swift Laboratories EGM scheduled
 ( Corporate News - 16-Feb-18   14:02 )
  Ind-Swift Lab extends Tuesday's rally
 ( Hot Pursuit - 23-Jul-14   12:03 )
  Ind-Swift Laboratories to conduct board meeting
 ( Corporate News - 28-Dec-19   10:09 )
  Ind-Swift Labs board to mull fund raising
 ( Hot Pursuit - 25-Jun-24   08:19 )
  Ind-Swift Laboratories standalone net profit rises 60271.43% in the December 2018 quarter
 ( Results - Announcements 12-Feb-19   16:25 )
Other Stories
  Adani Wilmar reports 13% volume growth in Q1 FY25
  06-Jul-24   14:44
  Tata Motors JLR wholesale rises 5% YoY in Q1
  06-Jul-24   13:01
  Marico's domestic biz sees modest volume growth in Q1
  06-Jul-24   12:25
  Titan revenue rises 9% YoY, adds 61 stores in Q1
  06-Jul-24   11:09
  Dabur India expects mid to high digit revenue growth in Q1
  06-Jul-24   10:40
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
  NSE SME Nephro Care India rallies on listing day
  05-Jul-24   14:45
Back Top